AV 2927
Latest Information Update: 15 Jan 1998
Price :
$50 *
At a glance
- Originator Triangle Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 15 Jan 1998 Discontinued-Preclinical for Respiratory syncytial virus infections in USA (Unknown route)
- 27 Jun 1995 Preclinical development for Respiratory syncytial virus infections in USA (Unknown route)